Several weeks ago, my colleagues Dr. Tom Hensing from North Shore Health System in Chicago, affiliated with the University of Chicago, and Dr. David Jackman from Dana Farber Cancer Institute in Boston, were kind enough to take the time to go over a series of cases in a webinar format. We reviewed the time line of several patients with advanced NSCLC, focusing on two central questions:

1) For various clinical situations, which molecular markers would you be inclined to recommend?

2) How would you be most inclined to have a patient approach an end to first line therapy and either continue ongoing maintenance therapy (continuation maintenance), transition to a new maintenance therapy (switch maintenance), or just hold off on treatment until there is evidence of progression and a clear reason to restart treatment.

The first case we covered is an elderly gentleman with a good performance status and an advanced squamous cell NSCLC. Here is the audio and video versions of the podcast, as well as the accompanying transcript and figures.

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-1-audio-podcast

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-1-transcript

drs-hensing-and-jackman-molec-testing-sequence-of-rx-case-1-figures

This program was sponsored by OSI Pharmaceuticals, who had no input in its content. We appreciate their support in making this activity possible.